


# THE PRO CHOICE IN ARTHRITIS



It is commonly agreed that prostaglandins confer upon the gastric mucosa a resistance to erosion and damage.<sup>1</sup> This so called mucoprotection is compromised by the use of antiarthritic drugs which are prostaglandin synthetase inhibitors. It has been suggested that this is of great relevance to the observed level of gastric side-effects observed with this class of drug.

Lederfen in the stomach has little or no effect on the mucoprotection conferred by the endogenous prostaglandins.<sup>2</sup> Simply, unmetabolised Lederfen is not a prostaglandin synthetase inhibitor.

The major metabolites of Lederfen are however most potent PSIs, shown by in vitro studies to be twice as potent as indomethacin.<sup>2</sup> Thus, once Lederfen



has been absorbed—avoiding prostaglandin-associated gastric compromise—a powerful antiarthritic effect is observed. Lederfen has been found to be at least equal in clinical effectiveness to reference standards including naproxen,<sup>3</sup> indomethacin,<sup>4</sup> and aspirin.<sup>5</sup> But with significantly fewer side-effects.

Power without doubt. The pro-choice in arthritis.

## Lederfen fenbufen TABLETS

the pro-drug way to  
control pain, stiffness  
and side-effects

**Indications:** Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis. **Dosage: Adults:** One tablet in the morning and two at night. LEDERFEN is not a gastric irritant and is converted, following absorption into long-acting active metabolites. Consequently LEDERFEN is extremely unlikely to cause gastro-intestinal bleeding or ulceration. Furthermore, LEDERFEN may be used without dosage modification in elderly patients in whom mild to moderate renal impairment commonly occurs. **Contra-indications:** Hypersensitivity to propionic acid anti-inflammatory drugs or aspirin. **Precautions:** In patients with a history or evidence of active peptic or intestinal ulceration, and only when considered essential in pregnant and nursing women. **Side-effects:** LEDERFEN is well tolerated by most patients. Gastro-intestinal symptoms, and occasionally skin rash are the most commonly reported. **Legal Category:** POM. **Presentation:** Light blue, film coated, capsule shaped 300 mg tablets engraved "LL300," or capsules printed "Lederle 300 mg," in bottles of 100. **Basic NHS Cost:** £16.24 per 100 tablets or capsules. PL/0095/0081. Further information is available on request to the company. **Lederle Laboratories, a division of Cyanamid of Great Britain Limited, Fareham Road, Gosport, Hants PO13 0AS. Tel: (0329) 236131.** **References:** 1. Guth PH, Ann Rev Med; 33: 183-196 (1982) 2. Birnbaum J, et al. Pharmacology; 25 (Suppl. 1): 27-38 (1982) 3. Khan FM, to be published 4. Salzman R T, Reid R T, Eur J Rheum and Inflamm; 5 (3) 318-325 (1982) 5. Roden DF, J Irish Med Assoc; 72 (No. 6.) 250-256 (1979).



Lederfen is a trademark.

# A RADICALLY NEW WAY TO DELIVER RELIEF FROM ARTHRITIS

unique pH-sensitive

**NEW**  
**ONCE-DAILY**  
**ORUVAIL**

2 CAPSULES o.d.

ketoprofen

Programmed to control your patients'  
symptoms 24 hours-a-day



dialysing membrane

ketoprofen

## IN THE STOMACH

the acid environment prevents  
release of active drug –  
minimising local gastric irritation.

## IN THE INTESTINE

the more alkaline environment

### Prescribing information

Dosage: Orally with food, 100-200mg three daily.  
Contra-indications: Recurring history of or severe ulceration or other duodenal ulcers; use in children or in patients intolerant to aspirin or other non-steroidal anti-inflammatory drugs; known to inhibit prostaglandin synthetase or with bronchial asthma or allergic disease.  
Precautions: Pregnancy: caution. Disease or conditions may be drug-binding drugs may need modification.  
Side-effects: Occasional gastrointestinal intolerance, with rare symptoms of haemorrhage, ulceration.  
Prescriptions: 100mg capsules P, 100, 200.  
Basis M&B Code: 100, 200, 100, 200mg capsules 29, 34.  
© May & Baker 1994




**M&B** May & Baker

May & Baker Ltd, Daresbury, Egerton Road, Macclesfield, Cheshire, SK10 2RN, UK

# THE ONLY SINGLE DRUG TREATMENT FOR ACUTE AND CHRONIC GOUT

NEW  
INDICATION



# RHEUMOX<sup>®</sup>

AZAPROPAZONE DIHYDRATE

Fast pain relief

Reduction of abnormal  
uric acid levels

## The unique analgesic

#### Uses

For the relief of acute and chronic gouty arthritis.

#### Dosage

For acute gouty arthritis, 100 mg (2 tablets) 4 times a day for 2-3 days, then 100 mg 3 times a day for 3-5 days. For chronic gouty arthritis, 100 mg 3 times a day.

#### Contra-indications

Patients with a known hypersensitivity to azapropazone or any of the excipients.

#### Precautions

Patients should be advised to avoid alcohol.

#### Side Effects

See the Summary of Product Characteristics for a full list of side effects.

#### Presentations


100 mg tablets, 100 mg sachets, 100 mg sachets, 100 mg sachets, 100 mg sachets, 100 mg sachets.

**A-H-ROBINS**

A. H. ROBINS COMPANY LIMITED  
Redkin Way, Horsham  
West Sussex, England RH13 5QP

# The logical choice

Select the correct figure from the six numbered ones



# **Voltarol<sup>®</sup>** diclofenac sodium **for osteoarthritis**

**Geigy**

Full prescribing information is available from Geigy Pharmaceuticals, Marshfield, West Sussex

GY 7

AZAPROPAZONE + PROQUAZONE + FEPRAZONE + OXAPROZIN + BENOXAPROFEN + CARPROFEN + SUPROFEN + KETOPROFEN + PIRPROFEN + ALMINOXIPROFEN + FENBUFEN + INDOBUFEN + BUTIBUFEN + FENCLOFENAC + FURFENOFENAC + DICLOFENAC + SULINDAC + CLIDANAC + ZOMEPIRAC + FENTIAZAC + ISOFEZOLAC + PIRAZOLAC + PIROXICAM + SUDOXICAM + OXAMETACIN + ACEMETACIN + ZIDOMETACIN + MEFENAMIC ACID + TOLFENAMIC ACID + FLUFENAMIC ACID + FLOCTAFENINE + ANTRAFENINE + FENDOSAL + FOSFOS

**...confused?**

**Thank goodness for**  
**BRUFEN 400**  
Ibuprofen B.P.

**The Great British  
Workhorse in arthritis**



Full prescribing  
information is  
available on request

Brufen is a registered trade mark

 The Boots Company Ltd, Nottingham

**New Product**

towards mobility

**Prescribing Information**

**Presentation**

White, uncoated, biconvex, scored tablets containing 200mg indoprofen.

**Indications**

Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and other musculo-skeletal disorders.

**Dosage**

**Osteoarthritis:** the recommended dosage of indoprofen is two tablets in the morning and one tablet at night. The night-time dosage may be increased to two tablets for patients with more severe pain.

**Rheumatoid Arthritis and Ankylosing Spondylitis:** the recommended dosage of indoprofen is two tablets in the morning and two tablets at night.

A relatively small group of patients may prefer to take one tablet three times or even four times daily. Flosint allows for this flexibility.

As with similar drugs, the tablets should be taken with food to diminish the risk of gastric irritation.

**Children:** Paediatric usage has not been established.

**Contra-Indications, Warnings, etc.** Sensitivity to this class of compounds, and active peptic ulceration.

**Warnings:** Bronchospasm may be precipitated in patients suffering from or with a previous history of bronchial asthma or allergic disease. Indoprofen is extensively protein-bound, and may displace oral anti-coagulants, sulphonylureas, etc. from binding sites. Dosage alterations may be needed in patients requiring concomitant treatment with these agents. Dosage reduction may be required in renal or hepatic impairment.

**Pregnancy:** The use of indoprofen during pregnancy should be avoided if possible, though animal experiments show no evidence of teratogenicity.

**Adverse Effects:** The most common adverse reactions caused by indoprofen are gastro-intestinal, including dyspepsia and nausea. Haemorrhage can occur rarely, as well as exacerbation of latent peptic ulceration. Other effects include mild central nervous system symptoms, such as dizziness and headache, and also skin rashes of various types. Decrease in platelet count has been observed rarely and blood dyscrasias may uncommonly occur. Limited data available suggest that abnormal liver function may be further impaired by treatment with indoprofen.

**Overdosage:** Gastric lavage and general supportive treatment should be carried out. There is no specific antidote.

**Legal Category**  
POM.

**Basic NHS Cost**

Container of 100 tablets-£15.00.

**Product Licence Number**

PL3433/0034.

**References**

1. *Eur. J. Rheumatol. Inflamm.* 1981; 4: 118.
2. *Ibid* 1981; 4: 74. 3. *Ibid* 1981; 4: 53. 4. *Brit. Med. J.* 1978; 1: 274. 5. *Clin. Trials J.* 1982; 19: 248. 6. *Eur. J. Rheumatol. Inflamm.* 1981; 4: 126. 7. *Ibid* 1981; 4: 135. 8. *Ibid* 1981; 4: 144.
9. *Curr. Ther. Res.* 1978; 24: 274. 10. *J. Oral Surg.* 1981; 39: 21.

Full prescribing information is available from  
MONTEDISON GROUP

 **FARMITALIA**  
**CARLO ERBA LTD.**

KINGMAKER HOUSE, STATION ROAD, BARNET,  
HERTS EN5 1 NU

Flosint is a registered trademark.

Flosint offers major anti-inflammatory/analgesic activity WITHOUT an unacceptable level of adverse effects, possessing both the powerful anti-inflammatory properties of indomethacin and the potent analgesic effects of the propionic acid derivatives.

Flosint is particularly suitable for treatment of a wide range of arthritic disorders including:

- Osteoarthritis
- Rheumatoid arthritis
- Ankylosing spondylitis
- Non-articular rheumatism



# without pain

Clinical evidence has confirmed that Flosint is at least as effective as other anti-inflammatory agents in relieving pain and inflammation<sup>1-5</sup> and is often better tolerated.<sup>5-8</sup>

# **FLOSINT**

**INDOPROFEN**

- Highly effective anti-inflammatory properties<sup>4,9</sup>
- Powerful, rapid relief of pain – superior in pain relief to paracetamol (650mg) plus dextropropoxyphene (100mg)<sup>10</sup>
- Well tolerated by most patients – no reports of onycholysis or phototoxicity in long-term studies<sup>6,7</sup>
- Dosage tailored to meet the patients changing needs – simple b.d. dosage.





in arthritis

# FLENAC<sup>®</sup>

fenclofenac

## a step beyond symptomatic relief

Flenac is not only a first-class treatment for arthritic pain and inflammation; recent studies<sup>1-4</sup> point to an extra benefit not shared by other non-steroidal anti-inflammatories.

These studies show Flenac to have a beneficial effect on E.S.R. and on C-reactive protein and Rheumatoid Factor titres – the laboratory parameters considered to best reflect disease activity and correlate with radiological evidence of joint damage<sup>5</sup>

reducing  
eventual joint  
damage

relieving pain  
and  
inflammation



**Prescribing information: Presentation** Tablets of 300mg fenclofenac. **Indications** Chronic and sub-acute rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, **Contra-indications** Active peptic ulceration or gastric bleeding. **Warnings** Flenac should not at present be prescribed for children or for pregnant or lactating women. Flenac should not be administered with anti-coagulants. Care should be taken when treating patients with known renal or hepatic dysfunction, eczema, asthma or sensitivity to other non-steroidal anti-inflammatory drugs. **Note** Flenac interferes with thyroid function tests. **Side-effects** Gastro-intestinal symptoms sufficient to require discontinuing treatment are rare. Rash has occurred but has usually subsided after withdrawal of the drug. **N.H.S. Price** £12.80 per box of 100. **P.L.** 44-0060 **References** 1. *Roy Soc Med (CSS)* 1980; No. 28, p.95-100. 2. *Roy Soc Med (CSS)* 1980; No. 28, p.177. 3. *Roy Soc Med (CSS)* 1980; No. 28, p.87-90. 4. *Roy Soc Med (CSS)* 1980; No. 28, p.109-112. 5. *Brit Med J* (1980); 280, p.964. Additional information is available from: Reckitt & Co. Pharmaceuticals Division, Hull HU8 7DS. Tel: 0482 26151. Flenac is a registered trademark.




**Today's  
solution.**



**Osmosis.**

# The tablet.

FLUID IS ABSORBED THROUGH  
SEMI-PERMEABLE MEMBRANE.



SOLUTION IS RELEASED  
CONTINUOUSLY  
AT A PRECISE RATE.

OSMOSIN is the tablet that releases therapy only in solution.

Designed to deliver a constant flow of relief from pain, inflammation and stiffness.

With a precision and regularity that no other oral therapy can achieve.

OSMOSIN releases a solution gradually and consistently which is absorbed throughout the digestive system.

To help minimise GI and CNS side effects associated with conventional therapies.

One tablet daily will provide full 24-hour efficacy, for most patients.

OSMOSIN is the principle of osmosis in a tablet.

**Osmosin**<sup>TM</sup>  
sodium indomethacin trihydrate

**Antiarthritic.**

FOR MOST ARTHRITIC

**OSMOSIN:** One tablet a day gives  
24-hour relief.

**OSMOSIN:** Highly effective relief  
from pain, inflammation and stiffness.

**OSMOSIN:** Minimises GI and  
CNS side effects.

*Rx Osmosin daily (30)*

**Abridged Product Information.**

Full prescribing information is available on request and should be consulted before prescribing.

**INDICATIONS** Osteoarthritis; rheumatoid arthritis; ankylosing spondylitis; acute musculo-skeletal disorders and low back pain. Pain and associated symptoms of primary dysmenorrhoea.

**DOSAGE** Usually one daily. If required one twice daily, take whole - do not chew or crush - and take with food or immediately after a meal. The maximum dose is two per day.

**CONTRA-INDICATIONS** Active peptic ulcer, history of gastro-intestinal lesions, sensitivity to indomethacin or other non-steroidal anti-inflammatory agents, children, lactating women, and pregnancy.

**PRECAUTIONS** If GI symptoms occur, weigh benefits against risks of continuing. If GI bleeding occurs discontinue OSMOSIN. May mask the signs and symptoms of infection. Use cautiously in the elderly and in patients with a history of psychiatric disorders, epilepsy or parkinsonism. Monitor the prothrombin time when adding OSMOSIN to the treatment of patients on anticoagulants. Interactions: aspirin, probenecid, lithium, frusemide, thiazides, beta-blockers.

**SIDE EFFECTS** OSMOSIN is usually well tolerated. GI symptoms including nausea, dyspepsia, are most common. Isolated cases of peptic ulcer and bleeding have been reported with indomethacin as have hepatic, CVS, and renal effects. CNS symptoms including headache, dizziness, rarely hypersensitivity - including skin rashes - and haematological reactions; ocular changes including blurred vision and corneal deposits have occurred.

**BASIC NHS COST** Each OSMOSIN Tablet is blue, coded 'OSMOSIN' and contains 105 mg sodium indomethacin trihydrate. Pack of 30 - Basic NHS price £10.80.

Product licence number: 0025 0148 Product authorisation number: 35 59 1

Issued November 1982

TM denotes trademark.



Merck Sharp & Dohme Limited, Hoddesdon, Hertfordshire, EN11 9BU

**Osmosin**<sup>TM</sup>  
sodium indomethacin trihydrate  
**Antiarthritic.**


# STATISTICS by T. D. V. SWINSCOW AT SQUARE ONE

from the **British Medical Journal**

The statistical testing of data is indispensable in many types of medical investigation and a help on countless occasions in clinical practice. This book provides step-by-step instruction. Subjects covered include standard deviation,  $\chi^2$  tests, t tests, non-parametric tests, and correlation. The book includes sections on Fisher's exact probability test and rank correlation not published in the *B.M.J.* series. Methods specially adapted to pocket calculators.

"The ability to put symbols in sequence may well be one of the greatest advances in man's development . . . This excellent and attractive volume will give you an idea into which category an article or projected article fits. The ink you save may be your own. It is superb value."  
O'Donnell, Barry, *British Medical Journal*, 1977, 1, 451.

" . . . this gem of a practical booklet squeezes the essence of biostatistics into 75 well-written, well-organized pages. Newcomers to the field will like the way obscure concepts are clarified; experts will find the book valuable as a teaching aid."  
de Jong, Rudolph, H., *J.A.M.A.*, 1977, 237, 1874.



---

**Seventh edition**

---

PRICE: Inland £2.50

Overseas US\$10.00  
including postage  
by air mail


*Payment must be enclosed with order or a surcharge of 50p will be made for rendering invoices and statements*

**ORDER YOUR COPY NOW**


*From: The Publisher,  
British Medical Journal,  
BMA House,  
Tavistock Square,  
London WC1H 9JR*

*or through any leading bookseller*


# Long term activity in arthritis




**I**N the treatment of arthritis, relief of pain and inflammation is a major objective. The ultimate aim, however, is to restore mobility lost through painful, stiffened joints. This requires long-term, consistently effective control of pain and inflammation. Continuity of treatment is fundamental to the successful management of arthritis.



**P**RODUCT of Boots Research, Froben is designed for the long-term treatment of arthritis. Rapidly absorbed, it quickly reaches the affected joints bringing pain and inflammation firmly under control and maintaining that control over long periods of treatment. Drug accumulation does not occur and Froben is well tolerated by most patients. Froben is suitable for continuous treatment. Which is why it is effective.



**S**UITABLE for most arthritic patients, Froben is particularly valuable for those who need a high level of relief from pain and inflammation. Froben will provide that extra relief without the high incidence of side-effects often associated with the more potent of the anti-arthritic agents.



**F**ROBEN is an excellent anti-arthritic with which to start treatment. It is an excellent antiarthritic with which to continue treatment. With Froben, your arthritic patients will receive the full benefit of continuous, consistent long-term therapy.

## Froben flurbiprofen Active in Arthritis


**Prescribing information:**


**Presentation:** Sugar coated tablets, each containing either 50mg or 100mg of flurbiprofen. **Uses:** Froben is indicated in the treatment of rheumatoid disease, osteoarthritis and ankylosing spondylitis. **Dosage:** 150mg to 200mg daily in 3 or 4 divided doses. In patients with severe symptoms or disease of recent origin, or during acute exacerbations, the total daily dose may be increased to 300mg in divided doses. **Contra-indications:** Warnings etc.: Froben should not be given to patients with peptic ulceration. Care should be taken when administering the drug to patients with asthma or who have experienced bronchospasm with other anti-inflammatory or analgesic agents. The safety of Froben during pregnancy or lactation has not been established. In animal experiments, no teratogenic effects were demonstrated but parturition was delayed and prolonged. Side-effects: dyspepsia, heartburn and headache are the commonest encountered. Occasional skin rashes have been reported. Treatment of overdose: gastric lavage and, if necessary, correction of serum electrolytes. There is no specific antidote. **Basic NHS Price:** 50mg tablets, 100 ES.24 100mg tablets, 100 E15.65. **Product Licence No:** 50mg tablets, PL0014/0167 100mg tablets, PL0014/0168. Further information is available on request.

If you have not yet used Froben, naturally you will wish to know more about the product than we can convey in this advertisement. We will gladly send you the Froben Clinical & Technical Review upon your request.

Name .....

Address .....

 The Boots Company Ltd Nottingham England



# 'CORDEX'

## SELF-BINDING CASES

*for easy and instant reference*

Made to hold one volume  
(6 issues) of your  
**ANNALS OF THE  
RHEUMATIC DISEASES.**

Each case is handsomely  
bound with a colour to  
complement the journal.  
Spring nylon cords, to carry  
the journals, slide freely along  
the spine of the binder. The  
name of the journal is gold-  
blocked on the spine. Date  
labels are also provided.

**Price:** Inland £4.00; Overseas US\$12.00  
including postage (air mail overseas) and packing

## **ORDER NOW**

*From:* The Subscription Manager,  
**ANNALS OF THE RHEUMATIC DISEASES**  
BMA House, Tavistock Square, London WC1H 9JR



**This Publication  
is available in  
Microform.**



**University Microfilms  
International**

Please send additional information  
for \_\_\_\_\_  
Name \_\_\_\_\_ (name of publication)  
Institution \_\_\_\_\_  
Street \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ Zip \_\_\_\_\_

300 North Zeeb Road  
Dept. P.R.  
Ann Arbor, Mi. 48106

**BRITISH JOURNAL  
OF  
RHEUMATOLOGY**

Formerly  
**RHEUMATOLOGY  
AND  
REHABILITATION**

Edited by Rodney Grahame

From 1983 the British Journal of Rheumatology assumes its new title. It will continue to maintain its principles of publishing both original and review articles of the highest standards whilst introducing new features. These include Editorials with commentaries on current thinking and Letters with discussion and development of ideas.

**Have you entered your  
subscription for 1983 yet?**

If not, please complete the  
form below.

To: Journals Department  
B T Distribution Centre  
8 Trident Way  
Southall, Middlesex UB2 5LS  
England

Please enter a new/renewal subscription for 1983 for the British Journal of Rheumatology Vol.22 at £25.00 (UK), \$73.00 (USA and Canada) and £32.00 (All other countries).

I enclose my remittance of. . . . .  
made payable to Baillière Tindall.

Please deliver to:  
Name . . . . .  
Address . . . . .  
. . . . .  
. . . . .  
. . . . .

**BAILLIÈRE TINDALL**